ZA958850B - Process for the preparation of a tetrazole derivative in two crystalline forms and crystalline form of said derivative - Google Patents

Process for the preparation of a tetrazole derivative in two crystalline forms and crystalline form of said derivative

Info

Publication number
ZA958850B
ZA958850B ZA958850A ZA958850A ZA958850B ZA 958850 B ZA958850 B ZA 958850B ZA 958850 A ZA958850 A ZA 958850A ZA 958850 A ZA958850 A ZA 958850A ZA 958850 B ZA958850 B ZA 958850B
Authority
ZA
South Africa
Prior art keywords
water
derivative
ray diffraction
diffraction pattern
contg
Prior art date
Application number
ZA958850A
Other languages
English (en)
Inventor
Antoine Caron
Dominique Chantreux
Colette Bouloumie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA958850B publication Critical patent/ZA958850B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
ZA958850A 1994-10-19 1995-10-19 Process for the preparation of a tetrazole derivative in two crystalline forms and crystalline form of said derivative ZA958850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412459A FR2725987B1 (fr) 1994-10-19 1994-10-19 Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Publications (1)

Publication Number Publication Date
ZA958850B true ZA958850B (en) 1996-05-27

Family

ID=9467986

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958850A ZA958850B (en) 1994-10-19 1995-10-19 Process for the preparation of a tetrazole derivative in two crystalline forms and crystalline form of said derivative

Country Status (26)

Country Link
US (1) US5629331A (cs)
EP (1) EP0708103B1 (cs)
JP (1) JP3366786B2 (cs)
KR (1) KR100251222B1 (cs)
CN (1) CN1061656C (cs)
AT (1) ATE198478T1 (cs)
AU (1) AU698041B2 (cs)
CA (1) CA2160725C (cs)
CY (1) CY2277B1 (cs)
CZ (2) CZ288629B6 (cs)
DE (1) DE69519788T2 (cs)
DK (1) DK0708103T3 (cs)
ES (1) ES2155115T3 (cs)
FI (1) FI114156B (cs)
FR (1) FR2725987B1 (cs)
GR (1) GR3035503T3 (cs)
HU (1) HU226461B1 (cs)
IL (1) IL115688A (cs)
NO (1) NO307516B1 (cs)
NZ (1) NZ280293A (cs)
PL (1) PL184193B1 (cs)
PT (1) PT708103E (cs)
RU (1) RU2144536C1 (cs)
SI (1) SI0708103T1 (cs)
TW (1) TW357147B (cs)
ZA (1) ZA958850B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
MY136446A (en) * 2000-07-19 2008-10-31 Novartis Ag New salts of valsartan
AU2002346694A1 (en) * 2001-12-10 2003-06-23 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
DE60308708T2 (de) * 2002-07-16 2007-08-23 Teva Pharmaceutical Industries Ltd. Neue synthese von irbesartan
EP1509517B1 (en) 2003-01-16 2008-06-11 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
ATE401323T1 (de) 2003-02-05 2008-08-15 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol- 5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4- on
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
WO2005011646A2 (en) * 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005051943A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Processes for the preparation of highly pure irbesartan
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
WO2006001026A1 (en) * 2004-06-23 2006-01-05 Hetero Drugs Limited Irbesartan polymorphs
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
ES2454197T3 (es) * 2004-11-11 2014-04-09 Lek Pharmaceuticals D.D. Formas polimórficas de Irbesartán
ES2259909B1 (es) * 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
EP1951714A1 (en) * 2005-07-27 2008-08-06 Jubilant Organosys Limited Process for producing 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl- 4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
SI1806130T1 (sl) 2006-01-09 2010-06-30 KRKA@@d@d@@@Novo@mesto Trden farmacevtski sestavek ki obsega irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
PL2065035T3 (pl) 2007-11-28 2011-02-28 Lesvi Laboratorios Sl Preparaty farmaceutyczne zawierające irbesartan
US20100234614A1 (en) * 2007-12-07 2010-09-16 Hetero Drugs Limited Process for pure irbesartan
KR101009383B1 (ko) * 2008-04-30 2011-01-19 켐젠주식회사 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법
WO2010116380A2 (en) * 2009-04-08 2010-10-14 Ctx Life Sciences Pvt. Ltd. A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan)
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
US8080670B2 (en) 2010-05-04 2011-12-20 Divi's Laboratories, Ltd. Process for the preparation of irbesartan
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
EP4408836A1 (en) 2021-10-01 2024-08-07 Sanofi Process for preparing sartan active compounds having a tetrazole ring

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
JP2697919B2 (ja) * 1989-09-29 1998-01-19 キヤノン株式会社 信号内挿回路及び該回路を備えた変位測定装置
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
ES2155115T3 (es) 2001-05-01
FR2725987B1 (fr) 1997-01-10
CZ271095A3 (en) 1996-05-15
NO954154L (no) 1996-04-22
CN1061656C (zh) 2001-02-07
PT708103E (pt) 2001-06-29
CA2160725C (en) 2001-12-18
EP0708103B1 (fr) 2001-01-03
AU698041B2 (en) 1998-10-22
DK0708103T3 (da) 2001-04-23
CY2277B1 (en) 2003-07-04
PL311012A1 (en) 1996-04-29
SI0708103T1 (en) 2001-04-30
GR3035503T3 (en) 2001-06-29
KR960014122A (ko) 1996-05-22
HU226461B1 (en) 2008-12-29
DE69519788T2 (de) 2001-08-30
KR100251222B1 (ko) 2000-05-01
CZ288629B6 (cs) 2001-08-15
PL184193B1 (pl) 2002-09-30
IL115688A (en) 1999-09-22
RU2144536C1 (ru) 2000-01-20
TW357147B (en) 1999-05-01
DE69519788D1 (de) 2001-02-08
US5629331A (en) 1997-05-13
EP0708103A1 (fr) 1996-04-24
CN1128261A (zh) 1996-08-07
FI114156B (fi) 2004-08-31
FI954992L (fi) 1996-04-20
NO307516B1 (no) 2000-04-17
HK1005135A1 (en) 1998-12-24
NO954154D0 (no) 1995-10-18
FR2725987A1 (fr) 1996-04-26
IL115688A0 (en) 1996-01-19
CZ288624B6 (cs) 2001-08-15
AU3433595A (en) 1996-05-02
JP3366786B2 (ja) 2003-01-14
HUT73179A (en) 1996-06-28
FI954992A0 (fi) 1995-10-19
JPH08208642A (ja) 1996-08-13
CA2160725A1 (en) 1996-04-20
ATE198478T1 (de) 2001-01-15
HU9503016D0 (en) 1995-12-28
NZ280293A (en) 1997-10-24

Similar Documents

Publication Publication Date Title
ZA958850B (en) Process for the preparation of a tetrazole derivative in two crystalline forms and crystalline form of said derivative
RU95118109A (ru) Способ получения производного тетразола, способ получения формы b производного тетразола, форма b производного тетразола и фармацевтическая композиция на основе производного тетразола формы b
PL320458A1 (en) Novel benzyl pyrimidines
CA2229000A1 (en) 1-biphenylimidazole derivatives, their preparation and their therapeutic use
ZA961677B (en) Method for recovery of xylose from solutions
JP2002543183A5 (cs)
CA2382406A1 (en) Substituted 2-arylbenzazole compounds and their use as antitumour agents
CA2123900A1 (en) Tetrazolylphenylboronic Acid Intermediates for the Synthesis of AII Receptor Antagonists
AU764260B2 (en) Method of producing cyclene
EP0398230A3 (en) Antiviral, highly water soluble, stable, crystalline salts of 2',3'-dideoxyinoside monohydrate, 2',3'-dideoxy-2',3'-didehydrothymidine monohydrate and 2',3'-dideoxy-2'-fluoroinosine hemihydrate
KR840003250A (ko) 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법
US6156890A (en) Process for the production of cyclene
大江真道 et al. Changes in the characteristic of dry matter production of Japonica type paddy rice (Oryza sativa L.) due to the Deep-water Treatment
JP2001062467A5 (cs)
CA2016765A1 (en) Antiviral, highly water soluble, stable, crystalline salts of 2',3'-dideoxyinosine monohydrate, 2',3'-dideoxy-2',3'-didehydrothymidine monohydrate and 2',3'-dideoxy-2'-fluoroinosine hemihydrate
Fuchigami et al. THE PREPARATION OF N 1-ALKOXYCARBONYL-N 2-(METHYLTHIO) THIOCARBONYLGUANIDINES VIA Δ4-l, 2, 4-THIADIAZOLINE DERIVATIVES
CA2081135A1 (en) Method for precipitating an organic resin from an alkaline solution thereof
RU99113400A (ru) Способ очистки сточных вод
FR2808844B1 (fr) Systeme permettant la recuperation de l'energie de la mer (houle)
Li et al. Synthesis of l-Arylaminoacetyl-4-arylacetyl Thiosemicarbazides